Neurotherapeutic Nanoparticle Compositions and Devices

Abstract

There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a neural stem cell and wherein the nanoparticles further comprise factors such as leukaemia inhibitory factor (LIF); XAV939 and/or one or more of : brain-derived neurotrophic factor (BDNF) or an agonist thereof; epidermal growth factor (EGF) or an agonist thereof; glial cell-derived neurotrophic factor (GDNF) or an agonist thereof; retinoic acid and derivatives thereof; ciliary neurotrophic factor (CTNF) or an agonist thereof; and Wnt5A. The biodegradable nanoparticles may deliver via controlled time release.

Description

RELATED APPLICATIONS[0001]This application is a continuation of International Application No. PCT / US2013 / 056246, which designated the United States and was filed on Aug. 22, 2013, published in English, which claims the benefit of U.S. Provisional Application No. 61 / 692,519, filed on Aug. 23, 2012 and U.S. Provisional Application No. 61 / 707,723, filed on Sep. 28, 2012. The entire teachings of the above applications are incorporated herein by reference.BACKGROUND OF THE INVENTION[0002]The invention is in the field of compositions for neuroprotection, particularly compositions that promote and protect neural cells in the central nervous system of a mammal such as a human. Also described are methods for repairing tissues of the central nervous system of a mammal such as a human. Neurodegenerative diseases represent the largest area of unmet clinical need in the Western world. They are characterised by a progressive loss of the structure or function of neurons in the nervous system (neur...

AI Technical Summary

Benefits of technology

[0028]According to an embodiment of the invention the nanoparticles suitably have a diameter of at least about 50 nm and at most about 300 nm; optionally at least about 100 nm and at most about 200 nm. Suitably the nanoparticles are capable of degrading of a period of time in order to effect timed release of the encapsulated LIF. Optionally the period of time may be selected from the group consisting of: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 days; 1, 2, 3, 4, 5 or 6 weeks; and up to six months.

Problems solved by technology

The process of neurodegeneration is not well understood and so the diseases that stem from it have no effective cures, nor is it possible to slow down their progression, as yet.

Chronic neurodegenerative disorders (NDD) of the central nervous system, which target the aging brain, are set to increase as the population ages and finding ways to better understand and treat these conditions is a major challenge given the personal and economic costs of these conditions.

However, as symptoms progress with time and coupled to the long-term use of dopaminergic drug therapies, a range of problems arise including the development of drug-induced motor complications such as “on-off” fluctuations and levodopa-induced dyskinesias (LID).

At this stage of the disease, drug therapies become increasingly disappointing in terms of a reliable therapeutic benefit.

These latter therapies can be effective, but only ever treat the symptoms without any attempt to repair the underlying and progressive disease.

Thus, these treatments also start to fail, in part because of this progressive nature of the non-nigral, non-motor aspects of Parkinson's Disease and in part because of the continued loss of nigral dopaminergic neurones.

Thus, NDD are characterised by a slow insidious progression with increasing misery for the patient and their family, and increasing burden on healthcare systems worldwide.

Early management is more in the community, but over time there are increasing co-morbidities that in turn greatly escalate costs in their management.

Thus, in cell therapy for PD, problems arise from the scarcity and ex vivo fragility of fetal dopaminergic cells.

However, such approachs have so-far failed to deliver substantial clinical benefits.

Whilst this exception proves that repair at the level of neuro-biochemistry is possible, viral-mediated delivery involves risk of unwanted side-effects due to viral components in addition to generating an immune response within the patient against the therapeutic protein itself.

Use of soluble growth factors alone is not simple, and may incur substantial off-target side-effects including the risk of carcinogenesis.

Images